Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioma 3 Myelodysplastic Syndromes 2 Leukemia, Myeloid, Acute 2 Diffuse Intrinsic Pontine Glioma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Obesity 1 Neoplasm Metastasis 1 Meningioma 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Disease 1 Carcinosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 7 lutetium Lu 177 dotatate 6 Specimen Handling 5 Bevacizumab 4 gallium Ga 68 dotatate 3 abemaciclib 3 Radiosurgery 3 Proton Therapy 3 Nivolumab 3 pembrolizumab 2 Surveys and Questionnaires 2 Sunitinib 2 Protons 2 Observation 2 ONC206 2 Ipilimumab 2 Hydroxyurea 2 Ga(III)-DOTATOC 2 Everolimus 2 Elasticity Imaging Techniques 2 CTLA-4 Antigen 2 ribociclib 1 regorafenib 1 olaparib 1 neratinib 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 capivasertib 1 cabozantinib 1 brigatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × TIC10 compound × 1 year × Clear all

NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡